Following people with long COVID for 4 years to find what shapes recovery
Follows 400 adults with long COVID to study symptoms, fatigue and blood vessel health.
Plain-language title generated from the registry record
Registry title: Predictors of Long-Term Evolution in Long COVID; 4-Year Follow-Up. (BioICOPER Follow-up Study)
Key facts
- Where
- Salamanca, SpainSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with long COVID who took part in the first BioICOPER study. It follows them four years later.
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- Long COVID diagnosed by WHO criteria, after a confirmed past SARS-CoV-2 infection
Main reasons for not taking part
- Acute illness that prevents taking part
- Cognitive or physical impairment that limits data collection
- Withdrawal of informed consent
- Under 18 years old
Read by machine on 12 November 2026.
Where in Spain
- Av. de Portugal 83. Planta 2Salamanca, SpainContact: Manuel Angel Gómez Marcos, Md, PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Instituto de Investigación Biomédica de Salamanca
- Trial code
- NCT07295483
- Record updated
- 12 March 2026
- Original description
Long COVID (persistent COVID) represents a major global health challenge due to its high prevalence (approximately 7%), significant impact on quality of life, and socioeconomic burden. Despite extensive research, diagnostic tools to objectively identify or predict long COVID evolution are still lacking.Read full original descriptionShow less
To Analyze the Determining Factors in the Evolution of Subjects Diagnosed With Long COVID at Four Years of Follow-up. BioICOPER Follow-up Study.
Long COVID (persistent COVID) represents a major global health challenge due to its high prevalence (approximately 7%), significant impact on quality of life, and socioeconomic burden. Despite extensive research, diagnostic tools to objectively identify or predict long COVID evolution are still lacking.
The BioICOPER Follow-up Study aims to analyze the influence of biomarker evolution on clinical symptomatology (particularly chronic fatigue) and vascular health after four years of follow-up among 400 participants previously included in the original BioICOPER cohort.
Advanced proteomic analysis, vascular function assessment, and machine-learning-based predictive modeling will be used to identify biomarkers associated with disease progression, stratified by sex. This project will contribute to personalized clinical management of long COVID and improved diagnostic and therapeutic strategies in primary care.
Inclusion: Adults ≥18 years old; Confirmed previous SARS-CoV-2 infection; Diagnosis of long COVID according to WHO criteria; Participation in the baseline BioICOPER study; Signed informed consent for re-evaluation.
Exclusion: Acute illness preventing participation; Cognitive or physical impairment limiting data collection; Age < 18 years old; Withdrawal of informed consent.